Sublobar resection versus lobectomy for patients with resectable stage I non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708,SURPRISE trial) - Sublobar resection versus lobectomy for patients with resectable stage I non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708,SURPRISE trial)

Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 500 人开始时间: 2018年5月24日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Synchronous or metachronous (within 5 years) malignancy except cancer with 5-year relative survival rate of 95% or more such as carcinoma in situ, intramucosal tumor, or early stage cancers 2) Active infection requiring systemic therapy. 3) Fever of 38 degree or higher at registration 4) Female during pregnancy, within 28 days of postparturition, or during lactation and male expecting partner's pregnancy 5) Severe psychological disorder 6) Receiving continuous systemic corticosteroid or immunosuppressant treatment 7) Uuncontrollable diabetes mellitus 8) Uncontrollable hypertension 9) Unstable angina, cardiac infarction within the past 6 months 10) Uncontrollable valvular disease or uncontrollable dilated cardiomyopathy or uncontrollable hypertrophic cardiomyopathy

发起方

Japan Clinical Oncology Group (JCOG)